Thursday, August 13, 2020

WuXi AppTec: Collaborating Against COVID-19

WuXi AppTec is convening and working together with experts, from our company and around the world, for ongoing analysis of the COVID-19 pandemic. We are also partnering with other industry leaders on actions to address it. As we continue to collaborate with...

WuXi’s STA Biotech CMC Outsourcing Boston Symposium Recap

WuXi’s STA Pharmaceutical recently hosted a knowledge sharing and networking symposium, “Biotech CMC Outsourcing Strategies – Boston.” More than 100 industry CMC professionals and collaborators participated in this event, which focused on perspectives and best practices for successful CMC outsourcing and global regulatory strategies....

WuXi Biologics Completes Construction of Asia’s Largest Perfusion Biologics Manufacturing Facility Using Disposable Bioreactors

We are pleased to announce the opening of our new commercial-scale cGMP biologics perfusion manufacturing facility in the city of Wuxi, China. The $150 million commercial biologics manufacturing facility accommodates two 1000L disposable bioreactors for perfusion processes, and is the largest perfusion biologics manufacturing facility...

WuXi’s STA Subsidiary Opens Operations in San Diego

We are delighted to announce that WuXi’s small-molecule process development and manufacturing subsidiary, Shanghai SynTheAll Pharmaceutical Co., Ltd. (STA), is opening operations in San Diego. STA will provide process R&D and API manufacturing services for early phase clinical studies through its San Diego facility,...

Subscribe to our Newsletter



Twitter LinkedIn